Skip to main content
For Healthcare
Professionals
Home
Therapeutic areas
Products
Resources
Events
Contact
English (United Kingdom)
Home
Therapeutic areas
Haematology
Immunology
Nephrology
Specialty Care portfolio
Products
▼Aspaveli® (pegcetacoplan)
Doptelet® (avatrombopag)
Kineret® (anakinra)
Orfadin® (nitisinone)
▼Zynlonta® (loncastuximab tesirine)
Resources
Events
Contact
Choose ALPROLIX®
Protection for tomorrow starts today*
1. ALTUVOCT Unmet need Adults
ALTUVOCT - UK landing page
Home
Therapeutic areas
Haematology
Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunology
Interleukin-1 and autoinflammatory diseases
Nephrology
C3G and IC-MPGN
Disease Pathophysiology
Patient Journey – Challenges
Disease Biomarkers
Video Series: Pathophysiology with Prof Matthew Pickering
Video Series: Paediatric nephrologist’s perspectives with Dr Dean Wallace
Stay In Touch
Specialty Care portfolio
ALTUVOCT - Unmet needs - UK+IRE
2. ALTUVOCT Unmet need Children
3. About ALTUVOCT for adults
Products
▼Aspaveli® (pegcetacoplan)
Doptelet® (avatrombopag)
About ITP
Challenge expectations
Efficacy
Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA
Dosing
Safety profile
Guidelines
Resources
Case studies
EVOLVE meeting hightlights
Podcast series for Ireland
Podcast series for UK
Kineret® (anakinra)
Home
About Kineret
About IL-1
Still’s disease
CAPS
FMF
Safety
Resources
Orfadin® (nitisinone)
▼Zynlonta® (loncastuximab tesirine)
Home
Efficacy
Post-CAR-T: LOTIS-2 sub-analysis
2-year follow up data
Post-CAR-T: Real-world evidence (RWE)
Dosing and administration
Overall Safety Profile
Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Myelosuppression, cytopenias management and dose modifications for AEs
Resources
Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Podcasts
4. About ALTUVOCT for children
Resources
5. Altuvoct - Resources
Events
Contact
Related information
PP-10275
Home
Therapeutic areas
Haematology
Haemophilia
Immune thrombocytopenia (ITP)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Immunology
Interleukin-1 and autoinflammatory diseases
Nephrology
C3G and IC-MPGN
Patient Journey – Challenges
Disease Biomarkers
Video Series: Pathophysiology with Prof Matthew Pickering
Video Series: Paediatric nephrologist’s perspectives with Dr Dean Wallace
Stay In Touch
Specialty Care portfolio
Products
▼Aspaveli® (pegcetacoplan)
Doptelet® (avatrombopag)
About ITP
Challenge expectations
Efficacy
Speed of onset and sustainability of response
Consistency of response
Effectiveness following switch from other TPO-RA
Dosing
Safety profile
Guidelines
Resources
Case studies
EVOLVE meeting hightlights
Podcast series for Ireland
Podcast series for UK
Kineret® (anakinra)
Home
About Kineret
About IL-1
Still’s disease
CAPS
FMF
Safety
Resources
Orfadin® (nitisinone)
▼Zynlonta® (loncastuximab tesirine)
Home
Efficacy
Post-CAR-T: LOTIS-2 sub-analysis
2-year follow up data
Post-CAR-T: Real-world evidence (RWE)
Dosing and administration
Overall Safety Profile
Non-haematological TEAEs
Haematological & laboratory TEAEs
Special warnings and precautions for use
Myelosuppression, cytopenias management and dose modifications for AEs
Resources
Expert opinion videos
Real World Experience case studies
BSH 2024 highlights
Podcasts
Resources
Events
Contact
Login
Other sites
expand_less